NEW YORK (GenomeWeb News) – Agilent Technologies and Seoul National University Hospital in South Korea are collaborating to develop and verify biomarkers for use in developing drugs, they announced Wednesday.
Drugs to be developed as part of the deal include narcotics and immune suppressants.
Agilent is supplying its 6460 Triple Quadrupole LC/MS system, as well as support services and application expertise to the work. The hospital will create and maintain "an optimal environment for new biomarkers to be identified and tested vigorously," the partners said.
Financial and other terms were not disclosed.
"Through this collaboration, we hope to establish [a] more effective and varied verifications system for the medical and life sciences industries," Rod Minett, general manager of Life Sciences, South Korea and the South Asia-Pacific region, said in a statement.